AptarGroup, Inc. (ATR) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage.
Is AptarGroup, Inc. stock overvalued or undervalued in 2026?
AptarGroup, Inc. (ATR) trades at 23.0× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (30.2×) $167 (+31 %); at its sector median (30.4×) $168 (+32 %).
Kaplio overview: AptarGroup, Inc.
Market cap $8B · 52 weeks $112 – $146 (12 % below the high) · P/E 23.0× · 2027 expected P/E 20.6× · Dividend 1.5 % · 11 years rising · Next earnings October 29, 2026 · expected EPS $1.47 · Closing price, Oct 28 · accounts published Jul 30.
- Valuation: P/E 23.0× (cheap).
- Business: ROIC 9 % (fair).
- Balance sheet: Net debt/EBITDA 1.4× (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At the decade median (30.2×) $167 (+31 %); at its sector median (30.4×) $168 (+32 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 7 pass
- R&D / Revenue 2.8 %, fails.
- Gross margin 29.6 %, fails.
- FCF / Net Income 76.3 %, fails.
- ROIC 9.1 %, fails.
- 5y EPS growth 12.5 %, passes.
- Net debt / EBITDA 1.4×, passes.
- P/E vs own 10y history 23.0×, passes.
Against its peers (reference peers) — AptarGroup, Inc.: P/E 23.0×; EV/EBITDA 11.3×; ROIC 9.2 %; $8.1B. Stevanato Group S.p.A. (P/E 36.3×; EV/EBITDA 17.3×; ROIC 6.4 %; $5.3B), West Pharmaceutical Services, Inc. (P/E 51.6×; EV/EBITDA 32.5×; ROIC 15.8 %; $28.4B), Sonoco Products Company (P/E —; EV/EBITDA 12.8×; ROIC -2.0 %; $4.8B).
Expensive or cheap against its last ten years?
P/E at each close: today 23.0× · median 30.2× · minimum 20.5× · maximum 47.4× · cheap below 26.7× · expensive above 36.2×. It has been cheaper than today only 8% of the time over its last ten years.
Dividend
solid · Yield 1.5 % ($1.84 per share in 2025) · Years raising it ≥ 11 · 5-year growth +5 % a year · Free cash flow coverage 2.7× · With $1,000 invested today you'd collect $15.20 a year ($1.27 a month).
Profitability
| Return on Equity | 13.52% |
| Return on Invested Capital | 9.15% |
| Return on Assets | 7.06% |
| Gross Margin | 28.26% |
| Operating Margin | 12.37% |
| Net Margin | 9.22% |
Financial Health
| Debt / Equity | 0.54 |
| Current Ratio | 1.61 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 3.81 |
Price Performance
| 1 month | +3.15% |
| 3 months | -5.07% |
| Year-to-date | +4.27% |
| 1 year | +2.30% |
| 3 years | +4.09% |
| 5 years | +5.29% |
| 10 years | +78.01% |
Dividend History
Paid in the last 12 months: $1.4400 per share in 3 payments.
| Date | Amount |
|---|---|
| 2026-07-30 | $0.4800 |
| 2026-05-06 | $0.4800 |
| 2026-02-04 | $0.4800 |
| 2025-10-23 | $0.4800 |
| 2025-07-24 | $0.4500 |
| 2025-05-01 | $0.4500 |
| 2025-02-05 | $0.4500 |
| 2024-10-24 | $0.4500 |
| 2024-07-25 | $0.4500 |
| 2024-04-24 | $0.4100 |
Amounts adjusted for stock splits.
Related companies: AMCR · WST · SON · SLGN · STVN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of ATR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks